Related references
Note: Only part of the references are listed.Reduced frequencies and functional impairment of dendritic cell subsets and non-classical monocytes in myelodysplastic syndromes
Nathalie Van Leeuwen-Kerkhoff et al.
HAEMATOLOGICA (2022)
Cancer testis antigens in myelodysplastic syndromes revisited: a targeted RNA-seq approach
Ana Maria Hurtado Lopez et al.
ONCOIMMUNOLOGY (2020)
Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it
Amer M. Zeidan et al.
BLOOD REVIEWS (2019)
VarSome: the human genomic variant search engine
Christos Kopanos et al.
BIOINFORMATICS (2019)
Co-delivery of human cancer-testis antigens with adjuvant in protein nanoparticles induces higher cell-mediated immune responses
Medea Neek et al.
BIOMATERIALS (2018)
A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia
Arjan A. van de Loosdrecht et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study - A Brief Research Report
Julie Westerlin Kjeldsen et al.
FRONTIERS IN IMMUNOLOGY (2018)
NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome
Elizabeth A. Griffiths et al.
CLINICAL CANCER RESEARCH (2018)
WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia
Hongtao Liu et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2018)
Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells
Jihao Zhou et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data
Vanessa Jurtz et al.
JOURNAL OF IMMUNOLOGY (2017)
Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells
Cornelia Siebenkas et al.
PLOS ONE (2017)
Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy
Yoshihiro Oka et al.
ONCOLOGY RESEARCH AND TREATMENT (2017)
Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome
Yasunori Ueda et al.
CANCER SCIENCE (2017)
DNA Methyltransferase Inhibitors in Myeloid Cancer Clonal Eradication or Clonal Differentiation?
Andreas Due Orskov et al.
CANCER JOURNAL (2017)
Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia
Sebastien Anguille et al.
BLOOD (2017)
Improving cancer immunotherapy with DNA methyltransferase inhibitors
Mohammad H. Saleh et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy
Pragya Srivastava et al.
ONCOTARGET (2016)
Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8(+) and CD4(+) T-cell responses with multiple specificities including a novel DR7-restricted epitope
P. Baumgaertner et al.
ONCOIMMUNOLOGY (2016)
Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic HematopoiesisMasters of Survival and Clonality?
Lisa Pleyer et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides
Jason Brayer et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma
Deepa K. Krishnadas et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B. Chiappinelli et al.
CELL (2015)
Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
Andreas D. Orskov et al.
ONCOTARGET (2015)
Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies
Antonio Di Stasi et al.
FRONTIERS IN IMMUNOLOGY (2015)
Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses
Benjamin Uttenthal et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies
A. O. Gang et al.
BLOOD CANCER JOURNAL (2014)
An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants
Christopher B. Fox et al.
EXPERT REVIEW OF VACCINES (2013)
Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1+ leukemias
Ekaterina Doubrovina et al.
BLOOD (2012)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells
Concetta Quintarelli et al.
BLOOD (2011)
Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies
Katayoun Rezvani et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia
Oliver Goodyear et al.
BLOOD (2010)
The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells
Maika Almstedt et al.
LEUKEMIA RESEARCH (2010)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Specific CD8+ T cell responses to HLA-A2 restricted MAGE-A3 p271-279 peptide in hepatocellular carcinoma patients without vaccination
Hua-Gang Zhang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2′-deoxycytidine in cutaneous melanoma:: Immunotherapeutic implications
Ester Fonsatti et al.
CLINICAL CANCER RESEARCH (2007)
Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation
Djordje Atanackovic et al.
BLOOD (2007)
Recombinant vaccinia/fowipox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients
Elke Jaeger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
The use of oil adjuvants in therapeutic vaccines
J Aucouturier et al.
VACCINE (2006)
Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer
A Mischo et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
CD8+T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden
O Goodyear et al.
BLOOD (2005)
Characterization of DNA demethylation effects induced by 5-aza-2′-deoxycytidine in patients with myelodysplastic syndrome
C Mund et al.
CANCER RESEARCH (2005)
Efficient identification of novel HLA-A*0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis
JH Kessler et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Share Paper
